Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company developing
potentially life-changing technologies for patients with cancer and diabetes,
today announced its issuance of an April 2020 Shareholder Letter. According to
the update, the letter highlights the Company’s progress with Oncoprex(TM), its
lead drug candidate with an initial targeted indication for non-small cell lung
cancer (“NSCLC”), its license agreement for a diabetes gene therapy drug
candidate, as well as other operational and business achievements. A digital copy of the letter can be found on the
Company’s website.
To view the full press release, visit http://ibn.fm/DyN7C
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with cancer and
diabetes. Genprex’s technologies are designed to administer disease-fighting
genes to provide new treatment options for large patient populations with
cancer and diabetes who currently have limited treatment options. Genprex works
with world-class institutions and collaborators to in-license and develop drug
candidates to further its pipeline of gene therapies in order to provide novel
treatment approaches. The Company’s lead product candidate, Oncoprex(TM), is
being evaluated as a treatment for non-small cell lung cancer (“NSCLC”).
Oncoprex has a multimodal mechanism of action that has been shown to interrupt
cell signaling pathways that cause replication and proliferation of cancer
cells; re-establish pathways for apoptosis, or programmed cell death, in cancer
cells; and modulate the immune response against cancer cells. Oncoprex has also
been shown to block mechanisms that create drug resistance. In January 2020,
the U.S. Food and Drug Administration granted Fast Track Designation for
Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib
(AstraZeneca’s Tagrisso(R)). For more information, please visit the company’s
website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is committed
to connecting subscribers with companies that have huge potential to succeed in
the short and long-term future. It is part of our mission statement to help the
investment community discover emerging companies that offer excellent growth
potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment